Center for Vaccine Research

What Center for Vaccine Research does

The Center for Vaccine Research (CVR) is an academic research center within the University of Pittsburgh School of Medicine that conducts vaccine and therapeutic development against emerging and re-emerging infectious diseases. Its research portfolio spans coronaviruses, influenza, arboviruses (Venezuelan and eastern equine encephalitis, Rift Valley fever), tularemia, tuberculosis, and HIV, with work extending from molecular biology through animal models to human cohort vaccine trials. CVR houses the Regional Biocontainment Laboratory, a BSL-3 and animal BSL-3 facility fully registered for work with select agents and CDC/USDA overlap pathogens, along with specialized aerobiology, radiotelemetry, plethysmography, and in vivo PET/CT imaging capabilities supporting rodent, ferret, rabbit, and nonhuman primate models.

The center is staffed by over 30 faculty members and hundreds of graduate students and postdoctoral researchers, led by Director Paul Duprex, who holds the Jonas Salk Chair for Vaccine Research. CVR operates under a non-commercial funding model, with operating support derived from federal grants (NIH R01/U01/P01 mechanisms, CDC, and the Department of Defense), University of Pittsburgh institutional support, and philanthropic donations. Revenue is not disclosed because the center does not sell products or services. Notable outputs include early SARS-CoV-2 isolation in February 2020, llama nanobody COVID-19 therapeutic development, and a $14.5 million Department of Defense award for mosquito-borne virus countermeasure research.

CVR's go-to-market is academic rather than commercial: it pursues influence through peer-reviewed publication, federal grant capture, inter-institutional collaboration (e.g., Washington University on VEEV decoy molecules, Albany Medical College on tularemia), and public science engagement including documentary films and media coverage. The center joined a multi-institution pandemic preparedness network in September 2024, positioning itself as a standing asset for preemptive response to high-consequence pathogen threats.

Name

Center for Vaccine Research

Legal name

Center for Vaccine Research

Website

https://cvr.pitt.edu

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

The Center for Vaccine Research is a University of Pittsburgh School of Medicine academic center that develops vaccines and therapeutics against emerging infectious diseases using BSL-3 containment facilities and animal models, funded primarily by NIH, CDC, and Department of Defense grants.

Ownership category

akta.pro rank

Product category

Academic Vaccine Research

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC)

akta.pro secondary industries

Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK), Pandemic Preparedness & Rapid-Response Vaccines (HLAIAEAF), Vaccine R&D, Clinical/Field Trials & Regulatory Affairs (HLAMAKAM), Disease-Specific Reference Laboratory Networks (e.g., TB, HIV, Influenza) (HLAJAIAD)

Keywords

• Vaccine research
• Infectious disease research
• Biocontainment laboratory
• Pandemic preparedness
• Virology research

Headquarters

HQ city

Pittsburgh

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain

Marketing channels5 records

Core offering

The Center for Vaccine Research (CVR) at the University of Pittsburgh conducts vaccine and novel therapeutic research against emerging and re-emerging infectious diseases. It operates specialized BSL-2, BSL-2+, and BSL-3/3+ biocontainment laboratories including the Regional Biocontainment Laboratory (RBL) registered for select agent work, providing end-to-end research capabilities from molecular biology through animal models to human cohort studies, with particular emphasis on respiratory and vector-borne pathogens.

Product overview

The Center for Vaccine Research (CVR) at the University of Pittsburgh is an academic research center focused on developing vaccines and novel therapeutics against emerging and re-emerging infectious diseases. The center provides research infrastructure including BSL-2, BSL-2+, and BSL-3/3+ laboratory facilities, animal biosafety level 3 laboratories, and the Regional Biocontainment Laboratory. CVR conducts vaccine trials, pathogen research (including coronavirus, influenza, tuberculosis, arboviruses, and other pathogens), and offers research collaboration opportunities rather than commercial products or services.

Differentiator

Problem solved

Functional benefit

Products and services

• Regional Biocontainment Laboratory (RBL)

Quantifiable outcome

• First US lab to receive SARS-CoV-2 samples in February 2020
• +3 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Washington University School of MedicinecoreStrategic or Co-development Partner · 18 November 2020Co-authored research on LDLRAD3 as a receptor for Venezuelan equine encephalitis virus. William Klimstra at CVR replicated findings using authentic virulent VEEV. Collaboration on decoy molecule drug development for mosquito-borne encephalitis viruses.
• Penn State Huck Institutes of the Life SciencesminorOthersDr. Suresh Kuchipudi previously held position as Dorothy Foehr Huck and J. Lloyd Huck Chair Professor in Emerging Infectious Diseases at Penn State before joining CVR. Research collaboration on zoonotic virus transmission and surveillance.
• Aeras Global TB Vaccine FoundationcoreStrategic or Co-development PartnerDr. Charles Scanga previously worked as Senior Scientist at Aeras coordinating and conducting studies to evaluate immunogenicity and protective efficacy of tuberculosis vaccine candidates using mouse, guinea pig, and non-human primate models.
• Centers for Disease Control and Prevention (CDC)coreStrategic or Co-development PartnerDr. Amy Hartman completed postdoctoral fellowship in Special Pathogens Branch at CDC. Worked on Ebola Zaire virus virulence factors and Marburg Hemorrhagic Fever outbreak response. Current collaboration on pandemic preparedness.
• University of Maryland-BaltimoreminorStrategic or Co-development PartnerCollaboration with Dr. Eileen Barry on tularemia vaccine research using attenuated strains of Francisella tularensis in New Zealand White rabbit model.
• Albany Medical CollegeminorStrategic or Co-development PartnerCollaboration with Dr. Karsten Hazlett on antibody and cell-mediated immune responses in tularemia rabbit models, exploring immune correlates of protection.
• Barratt-Boyes Laboratory, GSPHcoreStrategic or Co-development PartnerDeveloped first nonhuman primate model of lethal acute respiratory disease syndrome following H5N1 infection. Ongoing collaboration on universal flu vaccine and broadly-neutralizing antibody testing.

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Texas Biomedical Research Institute: San Antonio-based independent research institute operating one of the few BSL-4 laboratories in the US and conducting infectious disease and vaccine research. Comparable high-containment infrastructure and emerging pathogen portfolio.
• Wistar Institute: Independent biomedical research institute affiliated with the University of Pennsylvania focused on vaccine and infectious disease research. Directly comparable to CVR as a non-university vaccine/immunology research hub with BSL facilities, multiple NIH-funded PIs, and a translational research mandate.
• Trudeau Institute: Independent immunology and infectious disease research institute with animal model expertise for tuberculosis and respiratory pathogens. Directly comparable as an academic-style research organization studying immune correlates of protection.
• La Jolla Institute for Immunology: Independent research institute focused on immunology and vaccine science with strong NIH funding and postdoctoral training programs. Comparable academic-style research model and infectious disease focus.
• Emory Vaccine Center: Yerkes-affiliated vaccine research center at Emory University with strong BSL-3/ABSL-3 capabilities for HIV, influenza, and emerging pathogens. Comparable in scope, faculty breadth, and federal funding profile.
• Harvard Medical School Center for Virology and Vaccine Research: Harvard-based vaccine research center with BSL-2/3 capabilities working on HIV, TB, and emerging infections. Comparable in mission and funding sources, though embedded within a larger medical school ecosystem.
• University of Maryland Center for Vaccine Development: University-based vaccine R&D center conducting clinical and translational vaccine research against infectious diseases including influenza, malaria, and emerging pathogens. Closest peer to CVR in mission, federal funding mix, and BSL-2/3 lab infrastructure.
• Baylor College of Medicine - Vaccine Research: Academic vaccine research program at Baylor College of Medicine with BSL capabilities and NIH-funded investigators working on infectious diseases. Highly comparable as a university-based vaccine R&D center.

Broad incumbents

• Scripps Research - Immunology and Microbiology: Large independent research organization with substantial immunology, virology, and vaccine discovery programs. Comparable mission but operates at significantly broader scale across multiple disease areas.
• NIH/NIAID Rocky Mountain Laboratories: Federal research laboratory with BSL-4 capabilities conducting basic and applied research on viral and bacterial pathogens including VEEV, EEEV, and influenza. Operates at much larger scale than CVR with core federal appropriations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/PittCVR
• YouTubeyoutube.com/watch?v=D-3u1mQm1lA
• LinkedInlinkedin.com/company/the-center-for-vaccine-research

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Center for Vaccine Research